Meeting
2021 ASCO Annual Meeting
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
Presenter
Chung-Han Lee, MD, PhD
Memorial Sloan Kettering Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03635892
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4509)
DOI
10.1200/JCO.2021.39.15_suppl.4509
Abstract #
4509
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
Speaker: Chung-Han Lee, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Speaker: Juneko E. Grilley-Olson, MD
Videos & Slides
2023 ASCO Annual Meeting
First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.
Speaker: Chung-Han Lee, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
Speaker: Bradley Alexander McGregor, MD